<code id='AA0504834E'></code><style id='AA0504834E'></style>
    • <acronym id='AA0504834E'></acronym>
      <center id='AA0504834E'><center id='AA0504834E'><tfoot id='AA0504834E'></tfoot></center><abbr id='AA0504834E'><dir id='AA0504834E'><tfoot id='AA0504834E'></tfoot><noframes id='AA0504834E'>

    • <optgroup id='AA0504834E'><strike id='AA0504834E'><sup id='AA0504834E'></sup></strike><code id='AA0504834E'></code></optgroup>
        1. <b id='AA0504834E'><label id='AA0504834E'><select id='AA0504834E'><dt id='AA0504834E'><span id='AA0504834E'></span></dt></select></label></b><u id='AA0504834E'></u>
          <i id='AA0504834E'><strike id='AA0504834E'><tt id='AA0504834E'><pre id='AA0504834E'></pre></tt></strike></i>

          hotspot

          hotspot

          author:Wikipedia    Page View:49133
          US Capitol - SOTU
          Lawmakers in Congress have decided to punt efforts to reform how PBMs operate. BRENDAN SMIALOWSKI/AFP/Getty Images

          WASHINGTON — Congress has abandoned its attempt to reform how pharmacy middlemen operate in an upcoming package to fund the federal government, 11 lobbyists and sources following the talks told STAT.

          It’s a missed opportunity to pass one of the health care priorities that has attracted the most bipartisan interest and activity this Congress, though lawmakers could revive the negotiations on the issues in the future.

          advertisement

          Reforming how pharmacy benefit managers operate has been a top lobbying priority for the pharmaceutical industry since Democrats passed a major package aimed at lowering the costs of medicines in 2022. Pharma and PBMs have taken up a very public battle on the airwaves.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          leisure time

          Medical leaders decry Supreme Court decision on affirmative action
          Medical leaders decry Supreme Court decision on affirmative action

          STEFANIREYNOLDS/AFPviaGettyImagesMedicalleadersonThursdayreactedswiftlytotheSupremeCourt’sdecisionto

          read more
          Death of patient in Alzheimer’s trial raises question of possible risks
          Death of patient in Alzheimer’s trial raises question of possible risks

          APSTockTheexperimentalAlzheimer’sdruglecanemab,hailedafteritslowedpatients’cognitivedeclineinaclinic

          read more
          Activists slam private health insurers over coverage restrictions
          Activists slam private health insurers over coverage restrictions

          ProtestorsoutsideAmerica'sHealthInsurancePlansheadquarters.CourtesyPeople'sActionWASHINGTON—Hun

          read more

          Paxlovid study fails to answer questions over benefit for broader groups

          KobiWolf/BloombergPfizersaidTuesdaythatamuch-watchedstudyofitsantiviralPaxlovidinpatientswhohaveCovi